Patents by Inventor Hiroki Shirai

Hiroki Shirai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250085370
    Abstract: An MRI apparatus includes a measurement point determination unit that determines each measurement point of three-dimensional k-space data. In a case where a kx direction of a three-dimensional k-space is set as a readout direction, for a plurality of measurement points on a ky-kz plane, the measurement point determination unit adjusts a first condition that an angle of a straight line connecting the measurement points and a center of the plane changes with a golden angle (?) and a distance (r) from a center point of the plane monotonically increases, and determines the measurement point to satisfy a second condition that a change in a position of the measurement point is to be non-periodicity.
    Type: Application
    Filed: September 3, 2024
    Publication date: March 13, 2025
    Inventors: Tomoki Amemiya, Atsuro Suzuki, Yukio Kaneko, Suguru Yokosawa, Toru Shirai, Hiroki Shoji
  • Patent number: 12240362
    Abstract: A seat cushion frame configuring framework of a seat cushion for an occupant of a vehicle to sit on, and including left and right side frames, a cushion pan, and a reinforcement member. The left and right side frames are disposed at left and right side portions of the seat cushion. The cushion pan connects upper end portions of front portions of the left and right side frames together in a seat left-right direction. The reinforcement member includes the left and right reinforcement portions respective affixed to the seat left-right direction sides of the rear end portion of the cushion pan.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: March 4, 2025
    Assignees: NHK Spring Co., Ltd., Subaru Corporation
    Inventors: Syunichirou Osa, Hiroki Matsuda, Jun Shirai, Masafumi Takano, Fumito Kitanaka, Kenji Nagumo, Suguru Ishikawa
  • Patent number: 12227586
    Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: February 18, 2025
    Assignees: Astellas Pharma Inc., National Cancer Center
    Inventors: Yoshiyuki Tenda, Masatoshi Yuri, Shigenori Yagi, Yoshiki Satake, Kazunori Hirayama, Hiroki Shirai, Hiroki Sasaki, Fumiko Chiwaki, Masayuki Komatsu
  • Patent number: 12202908
    Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: January 21, 2025
    Assignee: Astellas Pharma Inc.
    Inventors: Toru Asano, Yorikata Sano, Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Michinori Akaiwa, Hiroyoshi Yamada, Nobuyuki Shiraishi
  • Publication number: 20240209108
    Abstract: An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon ? by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Applicants: Astellas Pharma Inc., National Cancer Center
    Inventors: Yoshiyuki TENDA, Masatoshi YURI, Shigenori YAGI, Yoshiki SATAKE, Kazunori HIRAYAMA, Hiroki SHIRAI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU
  • Publication number: 20230303658
    Abstract: The present invention provides a polypeptide comprising a modified Fc region of an IgG, and a modified Fcy receptor that binds specifically to the polypeptide, and methods for treating or preventing a disease or a disorder in a patient using immunotherapy.
    Type: Application
    Filed: August 18, 2021
    Publication date: September 28, 2023
    Inventors: Ryuichi Moriya, Hiroki Shirai, Shinji Soga, Naoko Shimada, David William Russell
  • Patent number: 11679166
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: June 20, 2023
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 11667724
    Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 6, 2023
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
  • Publication number: 20220096653
    Abstract: Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.
    Type: Application
    Filed: January 6, 2020
    Publication date: March 31, 2022
    Inventors: Michinori Akaiwa, Junya Ishida, Hiroki Toya, Nobuyuki Shiraishi, Toru Asano, Tomoaki Yoshikawa, Yorikata Sano, Hitoshi Doihara, Hiroki Shirai, Kazunori Hirayama
  • Publication number: 20210340276
    Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.
    Type: Application
    Filed: May 17, 2019
    Publication date: November 4, 2021
    Applicant: Astellas Pharma Inc.
    Inventors: Toru ASANO, Yorikata SANO, Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Michinori AKAIWA, Hiroyoshi YAMADA, Nobuyuki SHIRAISHI
  • Publication number: 20200261603
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 12, 2019
    Publication date: August 20, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20200171174
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 4, 2020
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20200123270
    Abstract: Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: July 6, 2018
    Publication date: April 23, 2020
    Inventors: Hitoshi Doihara, Kazunori Hirayama, Hiroki Shirai
  • Patent number: 10517966
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 31, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 10507251
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: December 17, 2019
    Assignee: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Publication number: 20190307906
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 10, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi MORINAKA, Hiroki SHIRAI, Kazunori HIRAYAMA, Naomi HOSOGAI, Hitoshi DOIHARA
  • Publication number: 20190269804
    Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Akifumi Morinaka, Hiroki Shirai, Kazunori Hirayama, Naomi Hosogai, Hitoshi Doihara
  • Patent number: 8946800
    Abstract: To provide a semiconductor device featuring reduced variation in capacitor characteristics. In the semiconductor device, a protective layer is provided at the periphery of the upper end portion of a recess (hole). This protective layer has a dielectric constant higher than that of an insulating layer placed in the same layer as the protective layer and configuring a multilayer wiring layer placed in a logic circuit region.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: February 3, 2015
    Assignee: Renesas Electronics Corporation
    Inventors: Ippei Kume, Kenichiro Hijioka, Naoya Inoue, Hiroyuki Kunishima, Manabu Iguchi, Hiroki Shirai
  • Patent number: 8648441
    Abstract: A semiconductor device has a substrate; a multi-layered interconnect formed on the substrate, and having a plurality of interconnect layers, each of which being configured by an interconnect and an insulating layer, stacked therein; a memory circuit formed in a memory circuit region on the substrate in a plan view, and having a peripheral circuit and at least one capacitor element embedded in the multi-layered interconnect; and a logic circuit formed in a logic circuit region on the substrate, wherein the capacitor element is configured by a lower electrode, a capacitor insulating film, an upper electrode, an embedded electrode and an upper interconnect; the top surface of the upper interconnect, and the top surface of the interconnect configuring the logic circuit formed in the same interconnect layer with the upper interconnect, are aligned to the same plane.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: February 11, 2014
    Assignee: Renesas Electronics Corporation
    Inventors: Kenichiro Hijioka, Ippei Kume, Naoya Inoue, Hiroki Shirai, Jun Kawahara, Yoshihiro Hayashi
  • Patent number: D1065479
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: March 4, 2025
    Assignee: Mitsubishi Electric Corporation
    Inventors: Shoichi Hirano, Kenshiro Kawabata, Shota Shirai, Yuji Tarumi, Yuji Motomura, Ryosuke Matsui, Hiroki Washiyama